

Use of non-prostanoic agonists of prostaglandin EP-2
and/or EP-4 receptors as cosmetic agents for
attenuating, reducing or stopping the loss of head hair
and other hairs.

The invention relates to the use of non-prostanoic
agonists of prostaglandin EP-2 and/or EP-4 receptors as
cosmetic agents for attenuating, reducing or stopping
loss of head hair and other hairs.

Man has a complement of 100 000 to 150 000 hairs and it
is normal to use 50 to 100 hairs daily. Maintenance of
this complement results essentially from the fact that
the life of a hair is subject to a hair cycle in the
course of which the hair forms, grows and falls out,
before being replaced with a new hair which appears in
the same follicle.

Three phases are observed in the course of a hair cycle,
namely: the anagenic phase, the catagenic phase and the
telogenic phase.

In the course of the first phase, known as the anagenic
phase, the hair passes through a period of active growth
associated with intense mitotic activity at the bulb.

The second phase, known as the catagenic phase, is
transient and is marked by an interruption of the mitotic
activity of the bulb. During this phase, the hair
undergoes an involution, the follicle becomes atrophied
and its dermal implantation moves upwards.

The end phase, known as the telogenic phase, corresponds
to a resting period of the follicle and the hair finishes

0917236.073001

by falling out. After this resting phase, a new follicle is regenerated, in the place of the previous one.

5 This process of permanent physical renewal undergoes a natural evolution in the course of ageing, the hairs become finer and their cycles shorter (M. Courtois et al., 1995, Br. J. Dermatol., 132: 86-93)..

10 In almost all cases, hair loss occurs in genetically predisposed individuals; it more particularly affects men.

15 This hair loss occurs when the process of physical renewal is accelerated or disrupted, i.e. the growth phases are shortened (Mr Courtois et al., 1994, Skin Pharmacol., 7: 84-89), the hairs pass to the telogenic phase earlier and they fall out in larger numbers. The successive growth cycles result in increasingly fine and increasingly short hairs, which become converted
20 gradually into an unpigmented down. This phenomenon may lead to baldness.

25 Compositions for preventing or reducing hair loss and optionally for inducing or stimulating hair growth have been sought for many years in the cosmetic or pharmaceutical industry.

30 In this perspective, compounds such as 6-1-(piperidyl)-2,4-pyrimidinediamine 3-oxide or "Minoxidil" have been used. The use of a lotion containing an azole derivative and most specifically 1-acetyl-4-{4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}piperazine for the treatment of alopecia is described in patent WO 92/00057.

35

In parallel, the article "Growth regulation of primary

09917236 073001
FOUO 9827660

human keratinocytes by prostaglandin E receptor EP₂ and EP₃ subtypes" by Konger et al. (Biochimica Biophysica Acta, 1401, 1998, 221-224) describes that prostaglandin receptors play an important role in regulating the growth of epidermal keratinocytes. It is also shown in the said article that prostanoid agonists of these prostaglandin receptors, for instance 11-deoxy PGE₁ induce a stimulation of epidermal keratinocyte growth.

Nevertheless, it is well known that the programmes of differentiation of the keratinocytes of the epidermis and of hair follicles are clearly different. Thus, it is known that differentiation markers such as keratins K1 and K10 are not expressed in hair follicles and in particular in the outer sheath (Lenoir et al., 1988, Dev. Biol. 130: 610-620); that trichohyalin is expressed in hair follicles, in particular in the inner sheath but not in the epidermis (O'Guin et al., 1992, J. Invest. Dermatol. 98: 24-32); and that type 1 cyclooxygenase is not expressed in the keratinocytes of hair follicles but is expressed in the epidermis (Michelet et al., 1997, J. Invest. Dermatol. 108: 205-209).

Furthermore, it is known that the keratinocytes of the epidermis and of hair follicles behave differently in response to the same pharmacological agent. Thus, it is known that, in vivo, treating the epidermis with retinoic acid induces hyperplasia and spongiosis (Griffiths et al., 1993, J. Invest. Dermatol. 101: 325-328) whereas treating the scalp induces a loss of hair (Berth-Jones et al., 1990, Br. J. Dermatol. 122: 75-755), and that, in vitro, retinoic acid, depending on the dose used, promotes or reduces the differentiation of the epidermis (Asselineau et al., 1989, Dev. Biol. 133: 32-335), while it causes an interruption of growth of the hair follicles (Billoni et al., 1997, Acta Dermatol. Venerol. 77:

09917236 073001

350-355). It is also known that EGF induces epidermal hyperplasia and, simultaneously, regression of the hair follicles (Philip et al., 1985, J. Invest. Dermatol. 84: 172-175).

5

Patent WO 98/33497 describes pharmaceutical compositions containing prostaglandins or prostaglandin derivatives which act as prostanoid agonists of the prostaglandin receptors in order to combat hair loss in man. In the
10 said document, prostanoid agonists of the type A_2 , $F_2\alpha$ and E_2 are preferred for treating hair loss.

The Applicant has now discovered that by using non-prostanoid agonists of the prostaglandin EP-2 and/or EP-4
15 receptors, a large induction and large stimulation in the growth of head hair and other hairs and strong action on slowing down the loss of head hair and other hairs are found, surprisingly.

20 The Applicant has thus found that the use in accordance with the invention makes it possible to obtain a rapid effect, at a low concentration and/or with a low rate of application.

25 Furthermore, the non-prostanoid agonists of the prostaglandin EP-2 and/or EP-4 receptors of the invention are particularly of low toxicity and show good conservation.

30 The use of these agonists makes it possible to obtain, in particular compared with those of the prior art, more effective compositions which may be used in particularly easy manner, and which also allow the compositions to be removed easily by simple rinsing.

35

The compounds in accordance with the invention are

094236.073001
FOOEEQ'9827660


5 Thus, one subject of the invention is the use of non-prostanoid agonists of prostaglandin EP-2 and/or EP-4 receptors as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs.

15 A subject of the invention is also the use of a non-prostanoid agonist of prostaglandin EP-2 and/or EP-4 receptors in a cosmetic composition and also in a cosmetic treatment process for attenuating, reducing or stopping the loss of head hair and other hairs.

The prostaglandin EP-2 and/or EP-4 receptors are receptors of prostaglandins of the E2 series. These receptors combine a family of 4 major representatives (EP1, EP2, EP3 and EP4) and have very varied tissue activities.

35 The prostaglandins are biological effectors derived from polyunsaturated fatty acid such as, for example, arachidonic acid for PGA_2 , PGE_2 , $\text{PGF}_2\alpha$ and TXA_2 , or from dihomo- γ -linolenic acid for PGE_1 . The prostaglandins are

involved in many physiological regulation phenomena. Prostanoid agonists of prostaglandin receptors are described in the article "Prostanoid Receptors: Structure, Properties and Functions" by Shush Narumya et al., Physiological review, Vol. 79, 1999, 1193-1226. These prostanoid agonists have in common a cyclopentane moiety of the type I:



An agonist is a compound which binds to a receptor and which induces a biological response similar to that obtained with the natural ligand which activates this response.

The expression "non-prostanoid agonist of prostaglandin EP-2 and/or EP-4 receptors" means a compound not comprising a cyclopentane ring of the type I, for attenuating, reducing or stopping the loss of head hair and other hairs. These agonists are capable of preventing or reducing the loss of head hair and other hairs and possibly of stimulating the growth of head hair and other hairs.

The term "other hairs" also means the eyelashes, the eyebrows and any hairs in general.

According to the invention, the said cosmetic composition may contain from 0.001% to 10% and preferably from 0.01% to 5% of non-prostanoid agonists of prostaglandin EP-2 and/or EP-4 receptors by weight relative to the weight of the composition.

It is also possible to use in addition other cosmetic

agents for stopping hair loss and/or increasing the growth of head hair and other hairs in the cosmetic compositions defined above, such as, for example, prostaglandin EP-3 receptor antagonists in proportions ranging from 0.001% to 10% and preferably from 0.1% to 5% of antagonists by weight relative to the weight of the composition, or alternatively compounds known for their properties on the loss and/or growth of head hair and/or other hairs, such as, for example, Minoxidil or 2,4-diaminopyrimidine 3-oxide or Aminexil.

The physiologically acceptable medium used for the compositions of the invention is a medium which can consist of water or a mixture of water and a solvent or a mixture of solvents. The solvents are chosen from acceptable organic solvents chosen more particularly from C1-C4 lower monofunctional or polyfunctional alcohols, for instance ethanol, isopropanol, tert-butanol, optionally oxyethylenated polyethylene glycols, polypropylene glycol esters, sorbitol and its derivatives, dialkyl isosorbides, glycol ethers and propylene glycol ethers, and fatty esters.

When they are present, the solvents are present in proportions of between 5% and 98% by weight relative to the total weight of the composition.

The composition may in addition contain a fatty phase. In this case, the fatty phase represents 0% to 50% of the total weight of the composition.

These compositions may also contain:

- esterified oligosaccharides such as those described in EP-A-0 064 012;
- hexosaccharic acid derivatives such as those described in EP-A-0 375 388, in particular glucosaccharic acid;

- 5 - glycosidase inhibitors such as those described in EP-A-0 334 586, in particular D-glycero-1,5-lactam;
- glycosaminoglycanase and proteoglycanase inhibitors such as those mentioned in EP-A-0 277 428, in particular L-galactano-1,4-lactone;
- tyrosine kinase inhibitors such as those described in EP-A-0 403 238, in particular 1-amido-1-cyano-(3,4-dihydroxyphenyl)ethylene;
- hyperaemiants such as:
- 10 • nicotinic acid esters including, more particularly, benzyl and C₁-C₆ alkyl nicotinate and in particular methyl and benzyl nicotinate, and also tocopheryl nicotinate;
- 15 • xanthine bases including, more particularly, caffeine and theophylline;
- capsaicin;
- UV-A and UV-B screening agents, for instance methoxycinnamates and benzophenone derivatives;
- phosphodiesterase inhibitors such as Visnadine®;
- 20 - adenine cyclase activators such as Forskolin;
- antioxidants and free-radical scavengers, in particular
- for OH radicals such as DMSO;
- α-tocopherol, BHA and BHT;
- superoxide dismutase (SODIUM);
- 25 - antidandruff agents such as omadine and octopirox;
- moisturizers such as urea, glycerol, lactic acid, α-hydroxy acids, thiamorpholinone and its derivatives, and lactones;
- antiseborrhoeic agents such as S-carboxymethylcysteine,
- 30 S-benzylcysteamine and derivatives thereof, and thioxolone;
- antiandrogens and hormones such as oestradiol, oestradiol, thyroxine, oxendolone and diethylstilbestrol;
- retinoids including, more particularly, t-trans-retinoic acid, also known as tretinoin, isotretinoin,
- 35 retinol or vitamin A and its derivatives, such as the

09917236 073001

acetate, palmitate or propionate, motretinide, etretinate and zinc t-trans-retinoate;

- antibacterial agents chosen, more particularly, from Irgasan, macrolides, pyranosides and tetracyclines, and

5 in particular erythromycin;

- calcium antagonists, among which mention may be made of Cinnarizine and Diltiazem as non-limiting examples;

- phospholipids such as lecithin;

10 - diazoxide (3-methyl-7-chloro-1,2,4-[2H]benzothiadiazine 1,1-dioxide);

- linoleic and linolenic acids;

- anthralin and its derivatives;

- 5-alkanol salicylic acid and its derivatives as described in patent FR-2 581 542;

15 - penetration activators such as THF, 1,4-dioxane, oleic acid, 2-pyrrolidone, benzyl salicylate, etc.,

- vitamins or provitamins such as β -carotene, biotin, panthenol and its derivatives, vitamin C and vitamins B₂, B₄ and B₆.

20

These compositions may also contain cyclic AMP.

These compositions may also additionally contain preserving agents, stabilizers, pH regulators, osmotic pressure modifiers, emulsifiers and conventional hydrophilic or lipophilic gelling agents and/or thickeners; hydrophilic or lipophilic active agents; preserving agents; antioxidants; fragrances; emulsifiers; moisturizers; pigmenting agents; depigmenting agents; 25 keratolytic agents; vitamins; emollients; sequestering agents; surfactants; polymers; acidifying or basifying agents; fillers; free-radical scavengers; ceramides; sunscreens; insect repellents; slimming agents; dyestuffs; bactericides; antidandruff agents.

35

The compositions in accordance with the invention may

09917236-072001

also contain surfactants including, in particular, those chosen from nonionic and amphoteric surfactants.

5 Among the nonionic surfactants, those which will be mentioned are the polyhydroxypropyl ethers described in particular in French patents Nos. 1 477 048; 2 091 516; 2 169 787; 2 328 763; 2 574 786; oxyethylenated (C_8-C_9)alkylphenols comprising from 1 to 100 mol of ethylene oxide and preferably 5 to 35 mol of ethylene oxide; 10 alkylpolyglycosides of formula: $C_nH_{2n+1} (C_6H_{10}O_5)_xH$ in which n ranges from 8 to 15 inclusive and x from 1 to 10 inclusive.

15 Among the amphoteric surfactants, those which will be mentioned more particularly are the amphocarboxyglycinates and amphocarboxypropionates defined in the CTFA dictionary, 3rd edition, 1982, and sold in particular under the name Miranol® by the company Miranol.

20 Cationic and/or anionic surfactants may also be used.

25 The compounds in accordance with the invention may also be introduced into gelled or thickened supports, such as essentially aqueous supports gelled with hetero-biopolysaccharides, such as xanthan gum, scleroglucans or cellulose derivatives, in particular cellulose ethers, aqueous-alcoholic supports gelled with polyhydroxyethyl acrylates or methacrylates or essentially aqueous 30 supports thickened in particular with polyacrylic acids crosslinked with a polyfunctional agent, such as the Carbopols sold by the company Goodrich.

35 The thickeners are preferably present in proportions of between 0.05% and 5% by weight and in particular between 0.2% and 3% by weight relative to the total weight of the

09947236-073001
T00E20"9E27T660

Needless to say, a person skilled in the art will take care to select the optional compound(s) to be added to the composition according to the invention, such that the advantageous properties intrinsically associated with the composition in accordance with the invention are not, or are not substantially, adversely affected by the addition envisaged.

The composition may have a pH of between 3 and 8.

These compositions defined above may be applied to the hair or the scalp and can be applied, for example, after washing the scalp and the hair with a shampoo.

A subject of the invention is also the use of a composition as defined above to attenuate, reduce or stop loss of head hair and other hairs. The agonists are used

in accordance with the invention to prevent or reduce the loss of head hair and other hairs and possibly to stimulate the growth of head hair and other hairs.

- 5 Another subject of the invention is a cosmetic or dermatological treatment process for attenuating, reducing or stopping the loss of head hair and other hairs, which consists in applying to head hair or other hairs a cosmetically or dermatologically effective amount
10 of non-prostanoic agonists of prostaglandin EP-2 and/or EP-4 receptors.

Another cosmetic treatment process for attenuating, reducing or stopping the loss of head hair and other
15 hairs consists in applying to head hair or other hairs a cosmetic or dermatological composition as defined above.

The examples which follow are intended to illustrate the invention without, however, being limiting in nature.
20

Example 1: LOTION FOR PREVENTING HAIR LOSS

Non-prostanoic agonist of prostaglandin			
EP-2 receptors			
		0.5	g
Propylene glycol			
		20	g
25	95° Ethanol	30	g
	Water	qs	100 g

This lotion is applied daily at a rate of 10 ml to the scalp for 2 to 3 months. A marked slowing down in the
30 daily loss of head hair and other hairs is then observed.

09947236.073001

Example II: SHAMPOO FOR PREVENTING HAIR LOSS

Non-prostanoic agonist of prostaglandin

EP-4 receptors 1.5 g

5

Polyglyceryl 3-hydroxylauryl ether 26 g A.M.

Hydroxypropylcellulose sold under the
name Klucell G by the company Hercules 2 g

Prostaglandin EP-3 receptor antagonist 1 g

10 Preserving agent qs

95° Ethanol 50 g

Aminexil 0.1 g

Water qs 100 g

15 This shampoo is used daily at a rate of 15 g per head of
hair, with an exposure time of about one minute, over a
period of 4 months. An appreciable slowing down in the
daily loss of hair is then observed.

20 **Example III: GEL FOR PREVENTING HAIR LOSS**

Non-prostanoic agonist of prostaglandin

EP-2 receptors 0.75 g

Essential oil of eucalyptus 1 g

Econazole 0.2 g

25 Lauryl polyglyceryl 6 cetearyl glycol
ether 1.9 g

Sodium glutamate of hydrogenated tallow,
sold under the name Acylglutamate HS110
by the company Ajinomoto 0.1 g

30 Preserving agents qs

Carbopol 934P sold by the company BF
Goodrich Corporation 0.3 g A.M.

Neutralizer qs pH 7

Water qs 100 g

35

09917236-073001

5

Non-prostanoid agonist of prostaglandin

EP-4 receptors 0.4 μ

20 q

20 q

0.1 q

qs 100 q

15

EXPERIMENT:

20

25

30

35

prostaglandin EP-2 and/or EP-4 receptors.

The fragments in the presence of the agonists thus
maintained in cell culture extend in a significantly
5 greater manner in comparison with the agonist-free
control fragment.

09017236 072001
T00E20 9E24T660